Please ensure Javascript is enabled for purposes of website accessibility

The 5 Best-Performing Big Pharma Stocks of 2013: BMY, ABBV, RHHBY, JNJ, AZN

By Max Macaluso – Jan 6, 2014 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical sector had a stellar 2013, but which stocks were the best?

The S&P 500 soared more than 32% in 2013, and several big pharma companies, namely Bristol-Myers Squibb (BMY -1.96%), AbbVie (ABBV -0.78%), Roche (RHHBY -2.12%), Johnson & Johnson (JNJ 0.92%), and AstraZeneca (AZN -2.77%) also performed extraordinarily well. The following slideshow reveals why these companies beat out their big pharma peers and what drove their strong performances in 2013.

Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences, ImmunoGen, and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.